3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
15
avelumab
12
Nivolumab
9
atezolizumab
5
Cyclophosphamide
5
fludarabine
4
Interleukin-2
4
ALT-803
4
durvalumab
3
cemiplimab
3
aldesleukin
3
Ipilimumab
3
domatinostat
2
budigalimab
2
Paclitaxel
2
Docetaxel
2
Bevacizumab
2
zimberelimab
1
venetoclax
1
talimogene laherparepvec
1
rovalpituzumab tesirine
1
regorafenib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
lorvotuzumab mertansine
1
glucopyranosyl lipid-A
1
epacadostat
1
efineptakin alfa
1
daromun
1
bempegaldesleukin
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled